drugset / Trial / NCT02285543
A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
To confirm the subgroup result from TPF (docetaxel, cisplatin and 5-fluorouracil ) trial (NCT01542931) that cN2 OSCC patients could benefit from TPF induction chemotherapy compared to the standard treatment.
Timeline
- Start
- 2016-12-01
- Primary completion
- 2023-07-30
- Completion
- 2023-07-30
Outcome
Outcome not reported
Stopped (Enrollment): “No new participants could be enrolled.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 750 mg/m2 | Intravenous |